tbuckley/cabot-search huggingface dataset:
Integrated multimodal cell atlas of Alzheimer’s disease
Authors: Mariano I. Gabitto, Kyle J. Travaglini, Victoria M. Rachleff, Eitan S. Kaplan, Brian Long, Jeanelle Ariza, Yi Ding, Joseph T. Mahoney, Nick Dee, Jeff Goldy, Erica J. Melief, Anamika Agrawal, Omar Kana, Xingjian Zhen, Samuel T. Barlow, Krissy Brouner, Jazmin Campos, John Campos, Ambrose J. Carr, Tamara Casper, Rushil Chakrabarty, Michael Clark, Jonah Cool, Rachel Dalley, Martin Darvas, Song-Lin Ding, Tim Dolbeare, Tom Egdorf, Luke Esposito, Rebecca Ferrer, Lynn E. Fleckenstein, Rohan Gala, Amanda Gary, Emily Gelfand, Jessica Gloe, Nathan Guilford, Junitta Guzman, Daniel Hirschstein, Windy Ho, Madison Hupp, Tim Jarsky, Nelson Johansen, Brian E. Kalmbach, Lisa M. Keene, Sarah Khawand, Mitchell D. Kilgore, Amanda Kirkland, Michael Kunst, Brian R. Lee, Mckaila Leytze, Christine L. Mac Donald, Jocelin Malone, Zoe Maltzer, Naomi Martin, Rachel McCue, Delissa McMillen, Gonzalo Mena, Emma Meyerdierks, Kelly P. Meyers, Tyler Mollenkopf, Mark Montine, Amber L. Nolan, Julie K. Nyhus, Paul A. Olsen, Maiya Pacleb, Chelsea M. Pagan, Nicholas Peña, Trangthanh Pham, Christina Alice Pom, Nadia Postupna, Christine Rimorin, Augustin Ruiz, Giuseppe A. Saldi, Aimee M. Schantz, Nadiya V. Shapovalova, Staci A. Sorensen, Brian Staats, Matt Sullivan, Susan M. Sunkin, Carol Thompson, Michael Tieu, Jonathan T. Ting, Amy Torkelson, Tracy Tran, Nasmil J. Valera Cuevas, Sarah Walling-Bell, Ming-Qiang Wang, Jack Waters, Angela M. Wilson, Ming Xiao, David Haynor, Nicole M. Gatto, Suman Jayadev, Shoaib Mufti, Lydia Ng, Shubhabrata Mukherjee, Paul K. Crane, Caitlin S. Latimer, Boaz P. Levi, Kimberly A. Smith, Jennie L. Close, Jeremy A. Miller, Rebecca D. Hodge, Eric B. Larson, Thomas J. Grabowski, Michael Hawrylycz, C. Dirk Keene, Ed S. Lein
Journal: Nature Neuroscience (2024)

Alzheimer's disease (AD) is the leading cause of dementia in older adults. Although AD progression is characterized by stereotyped accumulation of proteinopathies, the affected cellular populations remain understudied. Here we use multiomics, spatial genomics and reference atlases from the BRAIN Initiative to study middle temporal gyrus cell types in 84 donors with varying AD pathologies. This cohort includes 33 male donors and 51 female donors, with an average age at time of death of 88 years. We used quantitative neuropathology to place donors along a disease pseudoprogression score. Pseudoprogression analysis revealed two disease phases: an early phase with a slow increase in pathology, presence of inflammatory microglia, reactive astrocytes, loss of somatostatin
<i>Clostridium sporogenes</i> -derived metabolites protect mice against colonic inflammation
Authors: Felix F. Krause, Kira I. Mangold, Anna-Lena Ruppert, Hanna Leister, Anne Hellhund-Zingel, Aleksandra Lopez Krol, Jelena Pesek, Bernhard Watzer, Sarah Winterberg, Hartmann Raifer, Kai Binder, Ralf Kinscherf, Alesia Walker, Wolfgang A. Nockher, R. Verena Taudte, Wilhelm Bertrams, Bernd Schmeck, Anja A. Kühl, Britta Siegmund, Rossana Romero, Maik Luu, Stephan Göttig, Isabelle Bekeredjian-Ding, Ulrich Steinhoff, Burkhard Schütz, Alexander Visekruna
Journal: Gut Microbes (2024)

Gut microbiota-derived metabolites play a pivotal role in the maintenance of intestinal immune homeostasis. Here, we demonstrate that the human commensal
Weight Reduction and Target Serum Urate Level: A Longitudinal Study of Annual Medical Examination
Authors: Sho Fukui, Masato Okada, Tomohiro Shinozaki, Takahiro Suzuki, Takehiro Nakai, Hiroki Ozawa, Hiromichi Tamaki, Mitsumasa Kishimoto, Hiroshi Hasegawa, Takeaki Matsuda, Javier Marrugo, Sara K. Tedeschi, Hyon K. Choi, Daniel H. Solomon
Journal: Arthritis & Rheumatology (2024)

Objective Our objective was to evaluate associations of weight reduction with serum urate (SU) changes and achieving an SU level &lt;6 mg/dL in the real‐world setting, outside of specific weight reduction interventions. Methods We analyzed systematically collected data of annual medical examination participants from October 2012 to October 2022. Exposure was weight change (increase or decrease) between two consecutive visits, categorized as minimal (≤0.9 kg, reference), small (1.0–4.9 kg), moderate (5.0–9.9 kg), and large (≥10 kg). Outcomes included SU changes between two consecutive visits and achieving an SU level &lt;6 mg/dL in participants with hyperuricemia (SU level ≥7 mg/dL at the previous visit). Results We identified 58,630 eligible participants (median age 46 years, 51.3% female, 19.4% with overweight, median SU level 5.3 mg/dL, and 5.6% with a history of gout and/or hyperuricemia) with 336,814 visits over a median of 5.3 years. After adjustment for relevant covariates, linear general estimating equations estimated mean SU changes based on observed weight reductions (vs minimal changes) were as follows: small, −0.10 mg/dL (95% confidence interval [CI] −0.10 to −0.09 mg/dL); moderate, −0.34 mg/dL (95% CI −0.36 to −0.32 mg/dL); and large, −0.64 (95% CI −0.70 to −0.58 mg/dL). In participants with hyperuricemia, adjusted relative risks for achieving an SU level &lt;6 mg/dL by modified Poisson regression were 1.25 (95% CI 1.15–1.37) in small weight reductions, 2.82 (95% CI 2.43–3.27) in moderate weight reductions, and 5.27 (95% CI 4.15–6.70) in large weight reductions, with corresponding numbers needed to treat of 61.1 for small weight reductions, 8.5 for moderate weight reductions, and 3.6 for large weight reductions. Conclusion Small weight reductions were associated with only small SU changes. Some participants with hyperuricemia can achieve the target SU level with moderate to large weight reductions. image
<scp>JAK</scp> Inhibitors vs. Biologic <scp>DMARDs</scp>: Which is More Effective for Rheumatoid Arthritis Pain?
Authors: Abigail Weiland, Yvonne C. Lee
Journal: Arthritis & Rheumatology (2024)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
A tailored phytosomes based nose-to-brain drug delivery strategy: Silver bullet for Alzheimer's disease
Authors: Xiao Yue, Haihua Guo, Guanlin Wang, Jieyun Li, Zizhao Zhai, Zeting Wang, Wenhao Wang, Ziyu Zhao, Xiao Xia, Chuangxin Chen, Yingtong Cui, Chuanbin Wu, Zhengwei Huang, Xuejuan Zhang
Journal: Bioactive Materials (2024)
Response to Letter to the Editor: “Osteoarthritis: <scp>MRI</scp> Definitions and Disease Progression”
Authors: Alison H. Chang, Frank W. Roemer, Ali Guermazi, Orit Almagor, Jungwha (Julia) Lee, Joan S. Chmiel, Lutfiyya N. Muhammad, Jing Song, Leena Sharma
Journal: Arthritis & Rheumatology (2024)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association
Authors: Rakesh Gopinathannair, Brian Olshansky, Mina K. Chung, Steve Gordon, Jose A. Joglar, Gregory M. Marcus, Philip L. Mar, Andrea M. Russo, Uma N. Srivatsa, Elaine Y. Wan
Journal: Circulation (2024)

Cardiac arrhythmias are commonly noted in patients during infections with and recovery from COVID-19. Arrhythmic manifestations span the spectrum of innocuous and benign to life-threatening and deadly. Various pathophysiological mechanisms have been proposed. Debate continues on the impact of incident and exacerbated arrhythmias on the acute and chronic (recovery) phase of the illness. COVID-19 and COVID-19 vaccine–associated myocardial inflammation and autonomic disruption remain concerns. As the pandemic has transformed to an endemic, with discovery of new SARS-CoV-2 variants, updated vaccines, and potent antiviral drugs, vigilance for COVID-19–associated arrhythmic and dysautonomic manifestations remains. The objective of this American Heart Association scientific statement is to review the available evidence on the epidemiology, pathophysiology, clinical presentation, and management of cardiac arrhythmias and autonomic dysfunction in patients infected with and recovering from COVID-19 and to provide evidence-based guidance. The writing committee’s consensus on implications for clinical practice, gaps in knowledge, and directions for future research are highlighted.
ChiA: a major player in the virulence of Crohn’s disease-associated adherent and invasive <i>Escherichia coli</i> (AIEC)
Authors: Margot Fargeas, Frederic Faure, Clara Douadi, Caroline Chevarin, Aurélien Birer, Adeline Sivignon, Michael Rodrigues, Jérémy Denizot, Elisabeth Billard, Nicolas Barnich, Anthony Buisson
Journal: Gut Microbes (2024)

We investigated the role of ChiA and its associated polymorphisms in the interaction between Crohn's disease (CD)-associated adherent-invasive
Autophagy Blockage Enhancing Photothermal and Chemodynamic Synergistic Therapy Based on HCQ/CuS Nanoplatform
Authors: Ziye Wei, Weili Si, Mingjing Huang, Man Lu, Wenjun Wang, Chen Liang, Xiaochen Dong, Yu Cai
Journal: Advanced Healthcare Materials (2024)

Abstract As an intracellular protective mechanism, autophagy has the potential to significantly impair the therapeutic effects of photothermal therapy (PTT) and chemodynamic therapy (CDT), which helps cancer cells survive under harsh conditions, such as high temperature and reactive oxygen species (ROS). In this study, an autophagy blockage enhanced PTT and CDT synergistic therapy nanoplatform is constructed by loading hydroxychloroquine (HCQ) with autophagy inhibitory effect into hollow copper sulfide (HCuS). Specifically, HCuS produces toxic ROS through Fenton‐like reaction in the tumor microenvironment (TME). At the same time, PTT‐mediated temperature elevation of the tumor region accelerates the Fenton‐like reaction and ROS production, enhancing the therapeutic effect of CDT. Furthermore, the internal autophagy inhibitor HCQ significantly blocks the fusion of autophagosomes and lysosomes by deacidifying lysosomes, cutting off the self‐protection mechanism of cancer cells, and amplifying the combined treatment of PTT and CDT. Both in vitro and in vivo results demonstrate that the combination of photothermal‐enhanced chemodynamic therapy with inhibition of autophagy provides new insights into designing multifunctional therapeutic nanoagents.
Characterizing coagulation responses in humans and nonhuman primates following kidney xenotransplantation—A narrative review
Authors: Ali Zidan, Adham H. El‐Sherbini, Abdelrahman Noureldin, David K. C. Cooper, Maha Othman
Journal: American Journal of Hematology (2024)

Abstract The recent report of the first pig kidney transplant in a living human brings hope to thousands of people with end‐stage kidney failure. The scientific community views this early success with caution as kidney xenotransplantation exhibits many challenges and barriers. One of these is coagulation dysregulation. This includes (i) pig von Willebrand Factor (vWF) interaction with human platelets, which can induce abnormal clotting responses, heightening the risk of graft failure, (ii) the inefficiency of pig thrombomodulin in activating human protein C, which emphasizes the species‐specific variations that aggravate coagulation challenges, and (iii) the development of thrombotic microangiopathy in the pig grafts and the occurrence of systemic consumptive coagulopathy in the recipients. Indeed, coagulation dysregulation largely results from differences in endothelial cell response and incompatibilities between pig and human coagulation–anticoagulation pathways. These barriers can be resolved by modifications to pig vWF and the expression of human thrombomodulin and endothelial protein C receptors in pig cells, serving as strategic interventions to align the coagulation systems of the two species more closely. These coagulation challenges have clinical implications in how they affect graft survival and patient outcome. Genetic engineering of the organ‐source pig and the administration of various drugs have assisted in correcting this coagulation dysregulation. Hence, comprehending and controlling coagulation dysregulation is crucial for progress in xenotransplantation as a viable option for treating patients with terminal kidney disease.
Mosaic loss of chromosome Y, tobacco smoking, and risk of age-related lung diseases: insights from two prospective cohorts
Authors: Chenghao Weng, Yuxuan Zhao, Mingyu Song, Zilun Shao, Yuanjie Pang, Canqing Yu, Pei Pei, Ling Yang, Iona Y. Millwood, Robin G. Walters, Yiping Chen, Huaidong Du, Junshi Chen, Zhengming Chen, Giulio Genovese, Chikashi Terao, Jun Lv, Liming Li, Dianjianyi Sun
Journal: European Respiratory Journal (2024)

Background Little is known about the underlying relationship between mosaic loss of chromosome Y (mLOY), the most common chromosomal alterations in older men, and the risk of age-related lung diseases. Methods We included 217 780 participants from the UK Biobank and 42 859 participants from the China Kadoorie Biobank. The mLOY events were detected using the Mosaic Chromosomal Alterations pipeline. Outcomes included all lung diseases, chronic obstructive pulmonary disease (COPD), lung cancer, and idiopathic pulmonary fibrosis (IPF). Cox proportional hazard models were fitted to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of mLOY with lung diseases in both cohorts. The combined HRs were derived from meta-analysis. Results Results from two cohorts showed that expanded mLOY was associated with increased risks of all lung diseases [HR (95% CI): 1.19 (1.04, 1.37)], COPD [HR (95% CI): 1.20 (1.13, 1.28)], lung cancer [HR (95% CI): 1.34 (1.21, 1.48)], and IPF [HR (95% CI): 1.34 (1.16, 1.56) in UKB]. There was evidence of positive interactions between mLOY and smoking behavior [relative excess risk due to interaction (97.5%CI)&gt;0]. Additionally, we observed that current smokers with expanded mLOY had the highest risk of incident lung diseases in both cohorts. Conclusion mLOY may be a novel predictor for age-related lung diseases. For current smokers carrying mLOY, adopting quitting smoking behavior may contribute to substantially reduce their risk of incident lung diseases.
Comparison of oronasal and nasal mask in home mechanical ventilation: observational cohort and bench study
Authors: Emeline Fresnel, Christian Caillard, Marius Lebret, Léa Razakamanantsoa, Adrien Kerfourn, Johan Dupuis, Jean-François Muir, Elodie Lhuillier, Kinan El Husseini, Thomas Similowski, Antoine Cuvelier, Maxime Patout
Journal: European Respiratory Journal (2024)

Background In patients with chronic respiratory failure, home non-invasive ventilation (NIV) is delivered through nasal or oronasal masks. Masks are a cornerstone for NIV success but can be associated with side effects. However, the type, the frequency and the consequences of these side effects are unknown. Here, we aimed to study the prevalence, nature, and impact of mask-related adverse events in a cohort of stable patients. We then investigated differences between oronasal and nasal masks both in our cohort and in a bench study. Methods Prospective observational cohort including patients established on long-term non-invasive ventilation admitted for their elective review. Data regarding mask-related side effects were assessed using a structured questionnaire. Our bench study was performed using a 3-D printed head connected to an artificial lung. Results Eight hundred patients were included of whom, 84% had a oronasal mask. Moderate to very severe mask-related side effects occurred in 47% of patients and severe to very severe side effects occurred in 18%. Side effects were associated to a poorer daytime PaCO 2 (p=0.005), poorer subjective sleep quality (p=0.003), poorer quality of life (p&lt;0.001). Mask-related side effects were more frequently reported with the use of oronasal masks as compared to nasal masks (p=0.023). Our bench study showed that nasal masks were more stable than oronasal masks (p&lt;0.001). Conclusion Mask-related side effects are frequent and associated with poorer outcome. Our data suggest that nasal masks may have a better tolerance profile and should be used as a first-line interface.
Language and terminology to describe transgender communities; Perspectives from people with lived experience
Authors: Sav Zwickl, Foster Skewis, Tomi Ruggles, Joel Murray, Teddy Cook, Ada S. Cheung
Journal: International Journal of Transgender Health (2024)

Background There is no consensus over the meaning of "transgender," "trans and gender diverse," and other terminology used to describe people with a gender different from the gender presumed or recorded for them at birth. We aimed to survey transgender (trans) individuals to understand lived experience perspectives on terminology.
A personalised and systematically designed adherence intervention improves photoprotection in adults with Xeroderma Pigmentosum (XP): Results of the XPAND randomised controlled trial
Authors: Jessica Walburn, Sam Norton, Robert Sarkany, Martha Canfield, Kirby Sainsbury, Paul McCrone, Vera Araújo-Soares, Myfanwy Morgan, Janette Boadu, Lesley Foster, Jakob Heydenreich, Adrian P Mander, Falko F Sniehotta, Hans Christian Wulf, John Weinman
Journal: British Journal of Dermatology (2024)

Abstract Background Poor adherence to photoprotection in Xeroderma Pigmentosum (XP) increases morbidity and shortens lifespan due to skin cancers. Objective To test a highly personalised intervention (XPAND) to reduce the dose of ultraviolet radiation (UVR) reaching the face in adults with XP, designed using known psychosocial determinants of poor photoprotection. Methods A two-arm parallel group randomised controlled trial, including patients with sub-optimal photoprotection to receive XPAND or a delayed intervention control arm that received XPAND the following year. XPAND comprises seven one-to-one sessions targeting photoprotection barriers (e.g., misconceptions about UVR) supported by personalised text messages, activity sheets, and educational materials incorporating behaviour change techniques. The primary outcome, mean daily UVR dose-to-face across 21 days in June-July 2018, was calculated by combining UVR exposure at the wrist with a face photoprotection activity diary. Secondary outcomes were UVR dose-to-face across 21 days in August 2018, time spent outside, photoprotective measures used outside, mood, automaticity, confidence-to-photoprotect. Financial costs and quality-adjusted life years (QALYs) were calculated. Results 16 patients were randomised, 13 provided sufficient data for primary outcome analysis. The XPAND group (n=8) had lower mean daily UVR dose-to-face [0.03 SED (SD 0.02] compared to control (n=7) [0.36 SED (SD 0.16)] (adjusted difference=-0.25, p&amp;lt;0.001, Hedge’s g=2.2). No significant between-group differences were observed in time spent outside, photoprotection outside, mood, or confidence. The delayed intervention control showed improvements in UVR dose-to-face (adjusted difference=-0.05, Hedge’s g=-0.1) , time outside (adjusted difference=-69.9, Hedge’s g=-0.28), and photoprotection (adjusted difference=-0.23, Hedge’s g=0.45), after receiving XPAND. XPAND was associated with lower treatment costs (£-2642; 95% CI: -£8715 to £3873) and fewer QALYs (-0.0141; 95% CI: -0.0369 to 0.0028). Conclusions XPAND was associated with a lower UVR dose-to-face in XP patients and was cost-effective.
Uniting education, research, healthcare, and society to advance women’s heart health
Authors: Michael Y. Schakelaar, Annemieke Maas, Anne-Mar L.N. van Ommen, Anna E. Spiering, Roos de Jonge, Patrick Wijchers, Gerda van Rossum, Balthasar A. Heesters, Olivier G. de Jong, Jelle Zandveld, Heggert G. Rebel, Jan Meeldijk, Emma W. Pijnappel, Suzanne van Dijk, Alessia Di Maggio, Olaf Nijssen, Jorine G.F. Sanders, Lies Hoogerwerf, Mike van Spaandonk, Sandra Crnko, Thijs Koorman, Kevin Jenniskens, N. Charlotte Onland-Moret, Stefan M. van Geelen, Toine ten Broeke, Annet van Royen-Kerkhof, Gönül Dilaver, Sabrina Oliveira, Robbert J. Kok, Linda W. van Laake, Pim van der Harst, Wilko Spiering, Frans H. Rutten, Marco van Brussel, Hester M. den Ruijter, Niels Bovenschen
Journal: The Journal of Experimental Medicine (2024)

Complex health challenges require professionals to operate across disciplines and to better connect with society. Here, we showcase a community-engaged and challenge-based educational model in which undergraduate students conduct transdisciplinary research on authentic complex biomedical problems. This concept reinforces translational medicine, human capital, and exemplifies synergy between education, research, healthcare, and society.
P1.12A.10 Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFR-Mutated NSCLC
Authors: F. Sun, M.K. Banwait, A. Herrmann, Z. Piotrowska, K. Yun, L.A. Bazhenova, H.A. Wakelee, J.W. Neal, M.S. Das, K.J. Ramchandran, M. Roy, M. Diehn, N.J. Myall
Journal: Journal of Thoracic Oncology (2024)
P1.09C.03 IMMUNOResist: Defining the Immunophenotype of Immunotherapy Resistance with PD-L1 and CD8 Novel Tracer PET
Authors: F. Hegi-Johnson, T. Akhurst, T. John, A. Scott, S. Parakh, B. Blyth, S. Wong, M. MacManus
Journal: Journal of Thoracic Oncology (2024)
P2.04B.16 Real-World First Round Results from a Charity Lung Cancer Screening Program in East Asia
Authors: A.D.l. Sihoe, N.K.Y. Fong, A.S.m. Yam, M.M.W. Cheng, D.L.S. Yau, A.W.L. Ng
Journal: Journal of Thoracic Oncology (2024)
P2.04A.07 Improving IPN Management Through CAD and Virtual Nodule Clinics: A Prospective, Observational Multicenter Study (PINPOINT)
Authors: B.A. Willems, A. Leliveld, E.J.R. van Beek, L. Gorospe, A. Veltri, J.J. Visser, G.V. Scagliotti, J.G.J.V. Aerts
Journal: Journal of Thoracic Oncology (2024)
P1.13A.08 Biomarker Analysis of Camrelizumab Plus Nab-paclitaxel and Carboplatin as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer
Authors: J. Yu, C. Zhou, L. Wang, T. Jiang, A. Xiong, J. Yuan, W. Shi, S. Ren
Journal: Journal of Thoracic Oncology (2024)
P1.06C.05 The Impact of Lymphovascular Invasion as Prognostic Factor on Long-Term Survival in More Than 3500 Resected NSCLC Patients
Authors: F. Doerr, K. Grapatsas, N. Baldes, F. Oezkan, D. Theegarten, K. Darwiche, W.E.E. Eberhardt, M. Stuschke, H. Hautzel, K. Herrmann, P. Joubert, C. Taube, M. Forsting, M. Schuler, S. Bölükbas
Journal: Journal of Thoracic Oncology (2024)
P1.12B.05 Patient and Oncologist Preferences for ALK+ Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments
Authors: H. Le, J. Coulter, J.C. Cappelleri, H. Lu, M. Quaife, K. Meginnis, G. Fernandez, K. Culver, S. Vaghela, N. Rifi, T. Stinchcombe
Journal: Journal of Thoracic Oncology (2024)
P2.04B.14 Barriers to Maximal Screening Impact in Persons Diagnosed with Lung Cancer in a Prospective Cohort
Authors: W. Liao, J. Goss, T. Qureshi, S. Peppers, A. Harris, A. Porter, K. Dortch, A. Patel, F. Caro, J. Roma, W. Marshall, C. Fehnel, A. Mehrotra, O. Ogbeide, P. Lammers, K. Tonkin, J. Machin, J. Zhao, T. Ng, M. Ray, M.P. Smeltzer, R.U. Osarogiagbon
Journal: Journal of Thoracic Oncology (2024)
P2.07A.03 Prognostic Analysis of Completely Resected Lung Adenocarcinoma with Uncommon EGFR Mutations: CReGYT-01 EGFR Study
Authors: K. Hayasaka, N. Haratake, H. Notsuda, S. Katsumata, A. Hamada, K. Nomura, K. Fujino, M. Yoshikawa, K. Suzawa, K. Shien, K. Suda, S. Ohara, S. Fukuda, I. Kinoshita, S. Takamori, S. Muto, Y. Takanashi, K. Mizuno, A. Kawase, T. Hayakawa, K. Sekihara, M. Toda, S. Matsuo, K. Takegahara, M. Hashimoto, K. Nakahashi, M. Endo, H. Ozawa, R. Fujikawa, Y. Tomioka, K. Namba, T. Matsubara, J. Suzuki, H. Watanabe, K. Takada, H. Hoshino, T. Toyoda, Y. Koki, S. Shiono, M. Shimokawa, J. Soh, Y. Ohde, Y. Okada
Journal: Journal of Thoracic Oncology (2024)
P2.04B.09 A Qualitative Evaluation of the Critical Role of Lung Cancer Screening Program Navigators
Authors: L. Spalluto, K. Bonnet, D. Schlundt, C. Audet, C. Henschke, D. Yankelevitz, S. York, F. Hendler, D. Moghanaki, R. Dittus, C. Roumie, J. Lewis
Journal: Journal of Thoracic Oncology (2024)